Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

2.51
0.00 (0.00%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :0
Date :12-10-2024

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

10月 7th, 2024|Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt已关闭评论

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for [...]

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

6月 26th, 2024|Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock已关闭评论

NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board [...]

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

9月 21st, 2023|Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company已关闭评论

18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase [...]

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

8月 2nd, 2023|Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally已关闭评论

JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million, Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to [...]